Axillary dissection vs radiation for residual nodal disease after neoadjuvant systemic therapy 

Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel, discusses a debate held during the St. Gallen International Breast Cancer Conference on axillary dissection versus axillary radiation for residual nodal disease after neoadjuvant systemic therapy, touching on the potential omission of axillary dissection. The current standard of care in patients with residual disease within the nodes following primary systemic therapy is lymph node dissection, and recent trials have shown that over 60% of those patients will have residual disease. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.